|
Volumn 94, Issue 8, 2002, Pages 545-546
|
COX-2 in cancer - A player that's defining the rules
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
CELECOXIB;
CYCLOOXYGENASE 1 INHIBITOR;
CYCLOOXYGENASE 2;
CYCLOOXYGENASE 2 INHIBITOR;
EFLORNITHINE;
PIROXICAM;
PROSTAGLANDIN SYNTHASE INHIBITOR;
ROFECOXIB;
ANALGESIA;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
ARTHRITIS;
BLADDER CANCER;
CANCER INHIBITION;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG SYNTHESIS;
EDITORIAL;
ESOPHAGUS CANCER;
GASTROINTESTINAL DISEASE;
HIGH RISK PATIENT;
HUMAN;
IMMUNOSTIMULATION;
INTESTINE TUMOR;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
SKIN CANCER;
STRUCTURE ACTIVITY RELATION;
|
EID: 0037123340
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.8.545 Document Type: Editorial |
Times cited : (81)
|
References (17)
|